The objective of our study was to determine the peculiarity of vaccination against SARS-COV2 in patients with RD treated with biologic therapies
Latest Information Update: 23 Jun 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Elasomeran (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 23 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism